Effectiveness and Tolerability of Bisoprolol/Perindopril Single-Pill Combination in Patients with Arterial Hypertension and a History of Myocardial Infarction: The PRIDE Observational Study.
Angina
Arterial hypertension
Bisoprolol
Blood pressure
Coronary artery disease
Heart rate
Myocardial infarction
Perindopril
Single-pill combination
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
10
11
2022
accepted:
13
02
2023
medline:
29
5
2023
pubmed:
9
4
2023
entrez:
8
4
2023
Statut:
ppublish
Résumé
This study assessed the real-life effectiveness of a single-pill combination (SPC) of bisoprolol/perindopril for controlling blood pressure (BP) and symptoms of angina in patients with hypertension and a history of myocardial infarction (MI). Eligible patients with arterial hypertension and a history of MI were aged 18-79 years and had initiated bisoprolol/perindopril SPC within 3 months of study enrollment as part of routine Russian clinical practice. The primary endpoint was mean change in systolic and diastolic BP (SBP/DBP) at week 12 compared with baseline (data collected retrospectively). Secondary endpoints were assessed at weeks 4 and 12 and included mean change in resting heart rate (HR), proportion of patients reaching target level of resting HR, antianginal effectiveness of the SPC, and proportion of patients reaching target BP levels. A total of 504 patients were enrolled, of whom 481 comprised the full analysis set (mean age 61.4 ± 8.9 years, 68% men). Mean baseline SBP/DBP and HR values were 148.9 ± 16.8/87.7 ± 11.0 mmHg and 77.4 ± 10.5 bpm, respectively. Mean durations of hypertension and CAD were 12.8 ± 8.4 and 6.1 ± 6.3 years, respectively, and time since MI was 3.8 ± 5.3 years. At week 12, SBP/DBP had decreased by 24.9/12.2 mmHg (P < 0.001 vs baseline). Target BP (< 140/90 mmHg) was achieved by 69.8% and 95.9% of patients at weeks 4 and 12, respectively, and target HR (55-60 bpm) by 17.3% and 34.5% at weeks 4 and 12 versus 3.1% at baseline (P < 0.001). Reductions in angina attacks, nitrate consumption, and improvements in HR were statistically significant. Treatment was well tolerated. Treatment of symptomatic patients with CAD, hypertension, and a history of MI with a bisoprolol/perindopril SPC was associated with significant decreases in SBP/DBP and a high proportion of patients achieving BP treatment goals. This was accompanied by improvements in angina symptoms and reductions in HR in a broad patient population representative of those seen in everyday clinical practice. ClinicalTrials.gov Identifier NCT04656847.
Identifiants
pubmed: 37029871
doi: 10.1007/s12325-023-02462-9
pii: 10.1007/s12325-023-02462-9
pmc: PMC10220120
doi:
Substances chimiques
Perindopril
Y5GMK36KGY
Bisoprolol
Y41JS2NL6U
Antihypertensive Agents
0
Drug Combinations
0
Banques de données
ClinicalTrials.gov
['NCT04656847']
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2725-2740Informations de copyright
© 2023. The Author(s).
Références
Nguyen TN, Chow CK. Global and national high blood pressure burden and control. Lancet. 2021;398(10304):932–3.
pubmed: 34450082
doi: 10.1016/S0140-6736(21)01688-3
Zang J, Liang J, Zhuang X, Zhang S, Liao X, Wu G. Intensive blood pressure treatment in coronary artery disease: implications from the Systolic Blood Pressure Intervention Trial (SPRINT). J Hum Hypertens. 2022;36(1):86–94.
pubmed: 33589758
doi: 10.1038/s41371-021-00494-8
Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300.
pubmed: 19272490
doi: 10.1016/j.amjmed.2008.09.038
Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610–8.
pubmed: 21157368
doi: 10.1097/HJH.0b013e328342ca97
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004.
pubmed: 32371787
doi: 10.1097/HJH.0000000000002453
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.
pubmed: 30165516
doi: 10.1093/eurheartj/ehy339
World Health Organization. The selection and use of essential medicines 2019. https://www.who.int/publications/i/item/WHO-MVP-EMP-IAU-2019.05 . Accessed 3 Feb 2023.
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
pubmed: 31497854
doi: 10.1093/eurheartj/ehz486
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407–407.
pubmed: 31504439
doi: 10.1093/eurheartj/ehz425
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.
pubmed: 28886621
doi: 10.1093/eurheartj/ehx393
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367.
pubmed: 32860058
doi: 10.1093/eurheartj/ehaa575
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
pubmed: 34447992
doi: 10.1093/eurheartj/ehab368
Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015;65(6):1372–407.
pubmed: 25828847
doi: 10.1161/HYP.0000000000000018
O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–425.
pubmed: 23247304
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344–426.
pubmed: 25249585
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032.
pubmed: 35363499
Strauss MH, Hall AS, Narkiewicz K. The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovasc Drugs Ther. 2021. https://doi.org/10.1007/s10557-021-07248-1 .
doi: 10.1007/s10557-021-07248-1
pubmed: 34533690
Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S16-20.
pubmed: 2439789
Vincent M, Redmond G, Portevin B. Stereoselective synthesis of a new perhydroindole derivative of chiral iminodiacid, a potent inhibitor of angiotensin converting enzyme. Tetrahedron Lett. 1982;23:1677.
doi: 10.1016/S0040-4039(00)87188-9
Boytsov SA, Burtsev YP, Khomitskaya YV. Effectiveness and tolerability of the single-pill combination of bisoprolol and perindopril in patients with arterial hypertension and stable coronary artery disease in daily clinical practice: the STYLE study. Adv Ther. 2021;38(6):3299–313.
pubmed: 33991323
pmcid: 8189988
doi: 10.1007/s12325-021-01754-2
Abeel M, Gupta A, Constance C. Concomitant treatment of hypertensive patients with bisoprolol and perindopril in routine clinical practice: a post hoc analysis of the CONFIDENCE II, PROTECT I, and PROTECT III observational studies. Adv Ther. 2022;39(1):391–404.
pubmed: 34755324
doi: 10.1007/s12325-021-01958-6
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338: b1665.
pubmed: 19454737
pmcid: 2684577
doi: 10.1136/bmj.b1665
Kim J, Kang D, Park H, et al. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J. 2020;41(37):3521–9.
pubmed: 32542362
doi: 10.1093/eurheartj/ehaa376
Sabidó M, Thilo H, Guido G. Long-term effectiveness of bisoprolol in patients with angina: a real-world evidence study. Pharmacol Res. 2019;139:106–12.
pubmed: 30408572
doi: 10.1016/j.phrs.2018.10.031
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.
pubmed: 26724178
doi: 10.1016/S0140-6736(15)01225-8
The Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625–36.
doi: 10.1016/S0140-6736(21)00590-0
Lin ZP, Dong M, Liu J. Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial. Eur Rev Med Pharmacol Sci. 2013;17:794–801.
pubmed: 23609363
Yang T, Jiang Y, Hao Y, et al. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens Res. 2017;40(1):79–86.
pubmed: 27534738
doi: 10.1038/hr.2016.101
von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol. 1995;25(1):231–8.
doi: 10.1016/0735-1097(94)00345-Q
Morishita T, Tsutsui M, Shimokawa H, et al. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol. 2002;88(1):100–7.
pubmed: 11855668
doi: 10.1254/jjp.88.100
Lévy BI, Mourad JJ. Renin angiotensin blockers and cardiac protection: from basis to clinical trials. Am J Hypertens. 2022;35(4):293–302.
pubmed: 34265036
doi: 10.1093/ajh/hpab108
Mesnier J, Ducrocq G, Danchin N, et al. International observational analysis of evolution and outcomes of chronic stable angina: the multinational CLARIFY study. Circulation. 2021;144:512–23.
pubmed: 34261331
pmcid: 8360663
doi: 10.1161/CIRCULATIONAHA.121.054567
Eisen A, Bhatt DL, Steg PG, et al. Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Am Heart Assoc. 2016;5(10): e004080.
pubmed: 27680665
pmcid: 5121505
doi: 10.1161/JAHA.116.004080
Fox KM, EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–8.
pubmed: 13678872
doi: 10.1016/S0140-6736(03)14286-9
Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Fox KM. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: a EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J. 2015;170(6):1092–8.
pubmed: 26678630
doi: 10.1016/j.ahj.2015.08.018
Brugts JJ, Bertrand M, Remme W, et al. The treatment effect of an ACE-inhibitor based regimen with perindopril in relation to beta-blocker use in 29,463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials. Cardiovasc Drugs Ther. 2017;31(4):391–400.
pubmed: 28856537
pmcid: 5607906
doi: 10.1007/s10557-017-6747-9
Arós F, Loma-Osorio A, Vila J, et al. Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO II [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry]. Rev Esp Cardiol. 2006;59(4):313–320.
Castellano JM, Pocock SJ, Bhatt DL, et al. Popylill strategy in secondary cardiovascular prevention. N Engl J Med. 2022;387:967–77.
pubmed: 36018037
doi: 10.1056/NEJMoa2208275
Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study. Arch Intern Med. 2009;169(16):1491–9.
pubmed: 19752407
doi: 10.1001/archinternmed.2009.295
Jespersen L, Abildstrøm SZ, Hvelplund A, Prescott E. Persistent angina: highly prevalent and associated with long-term anxiety, depression, low physical functioning, and quality of life in stable angina pectoris. Clin Res Cardiol. 2013;102(8):571–81.
pubmed: 23636227
doi: 10.1007/s00392-013-0568-z
Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation. 1993;88(1):92–100.
pubmed: 8319361
doi: 10.1161/01.CIR.88.1.92
Pratt CM, McMahon RP, Goldstein S, et al. Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study). Am J Cardiol. 1996;77(15):1302–9.
pubmed: 8677870
doi: 10.1016/S0002-9149(96)00196-8
Kop WJ, Verdino RJ, Gottdiener JS, O’Leary ST, Bairey Merz CN, Krantz DS. Changes in heart rate and heart rate variability before ambulatory ischemic events. J Am Coll Cardiol. 2001;38(3):742–9.
pubmed: 11527627
doi: 10.1016/S0735-1097(01)01451-6
Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685–92.
pubmed: 22169130
doi: 10.1016/j.amjcard.2011.10.025
Steg PG, Greenlaw N, Tardif JC, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J. 2012;33(22):2831–40.
pubmed: 22922505
pmcid: 3498005
doi: 10.1093/eurheartj/ehs289
Ferrari R, Fox K. Heart rate reduction in coronary artery disease and heart failure. Nat Rev Cardiol. 2016;13(8):493–501.
pubmed: 27226153
doi: 10.1038/nrcardio.2016.84
Kobalava Z, Khomitskaya Y, Kiyakbaev G, ATHENA trial investigators. AchievemenT of target resting HEart rate on beta-blockers in patients with stable angiNA and hypertension (ATHENA) in routine clinical practice in Russia. Curr Med Res Opin. 2014;30(5):805–11.
pubmed: 24400847
doi: 10.1185/03007995.2013.874993
Ogilvie R, Sanjiv A, Roy P, De Souza S. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors. An open-label, observational, multicentre, general practice-based study. Clin Drug Invest. 2008;28(11):673–86.
doi: 10.2165/00044011-200828110-00001
Tsoukas G, Anand S, Yang K, CONFIDENCE Investigators. Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. Am J Cardiovasc Drugs. 2011;11(1):45–55.
pubmed: 21265582
doi: 10.2165/11587000-000000000-00000
Esler M, Kjeldsen SE, Pathak A, Grassi G, Kreutz R, Mancia G. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Blood Press. 2022;31(1):210–24.
pubmed: 36029011
doi: 10.1080/08037051.2022.2110858